Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GDK Bio
Rockville, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
GDK Bio is a clinical-stage biotechnology company focused on developing novel precision oncology therapies that target the tumor microenvironment. The company's lead program, GDK-001, is a first-in-class small molecule inhibitor of GCN2 (EIF2AK4), a key stress-response kinase that helps cancer cells survive in nutrient-poor conditions. By inhibiting GCN2, GDK Bio aims to disrupt the metabolic adaptation of tumors and enhance the immune system's ability to attack cancer cells. Headquartered in Rockville, Maryland, the company leverages its proprietary discovery platform to build a pipeline of innovative treatments for patients with advanced solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on GDK Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDK Bio.